Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.38 |
| ▸ | HTR2B | P41595 | 9/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | KHK | P50053 | 3/20 | 0.34 |
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14754056 | 0.83 | HTR6 (0.35) | HTR2CHTR2BCCNT1CDK9HTR6 | |
| SCHEMBL21729492 | 0.80 | HTR2C (0.38) | HTR2CHTR2BCCNT1CDK9HTR6 | |
| SCHEMBL15828742 | 0.80 | CCNT1 (0.36) | HTR2CHTR2BCCNT1CDK9HTR6 | |
| SCHEMBL24119205 | 0.78 | HPGD (0.33) | HTR2CHTR2BKHK | |
| SCHEMBL14197801 | 0.75 | SLC18A3 (0.37) | — | |
| SCHEMBL22306951 | 0.72 | SOS1 (0.31) | — | |
| SCHEMBL235884 | 0.69 | HTR6 (0.42) | HTR2CHTR2BHTR6KHK | |
| SCHEMBL14365465 | 0.69 | HTR6 (0.47) | HTR2CHTR2BHTR6KHKHTR2A | |
| SCHEMBL14197803 | 0.69 | GRIN2B (0.45) | — | |
| SCHEMBL29501433 | 0.69 | SLC18A3 (0.50) | HTR2CHTR2BHTR2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317111-A1 | NOVEL MEDICAMENT FOR TREATING INFLAMMATORY BOWEL DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-10-14 | — | — | US | disclosed |
| US-20210032207-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-04 | — | — | US | disclosed |
| WO-2020036154-A1 | NOVEL MEDICAMENT FOR TREATING INFLAMMATORY BOWEL DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-02-20 | — | — | WO | disclosed |
| US-20200055823-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2020-02-20 | — | — | US | disclosed |
| US-20190077762-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3318557-A2 | QUINOLONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2018-05-09 | — | — | EP | disclosed |
| US-20170362180-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170362180-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20160340314-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2016-11-24 | — | — | US | disclosed |
| US-20160340314-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2016-11-24 | — | — | US | disclosed |
| US-9440951-B2 | Quinolone compound | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150239865-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2015-08-27 | — | — | US | disclosed |
| US-20150239865-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2015-08-27 | — | — | US | disclosed |
| US-9067887-B2 | Quinolone compound | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2015-06-30 | — | — | US | disclosed |
| US-9067887-B2 | Quinolone compound | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2015-06-30 | — | — | US | disclosed |
| US-20150005287-A2 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-01 | — | — | US | disclosed |
| US-20150005287-A2 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-01 | — | — | US | disclosed |
| US-20140179675-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| US-20140179675-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| WO-2013029548-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239865-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | HTR2C 1561/4885HTR2B 2122/4885CCNT1 883/4885 |
| US-20170362180-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | HTR2C 1561/4885HTR2B 2122/4885CCNT1 883/4885 |
| US-20200055823-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | HTR2C 1561/4885HTR2B 2122/4885CCNT1 883/4885 |
| US-20160340314-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | HTR2C 1561/4885HTR2B 2122/4885CCNT1 883/4885 |
| US-20150005287-A2 | QUINOLONE COMPOUND | HAX1, NQO2, VIP | HTR2C 1655/4885HTR2B 2253/4885CCNT1 1021/4885 |
| US-20190077762-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | HTR2C 1579/4885HTR2B 2077/4885CCNT1 953/4885 |
| US-20140179675-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | HTR2C 1561/4885HTR2B 2122/4885CCNT1 883/4885 |
| US-20210032207-A1 | QUINOLONE COMPOUND | HAX1, NQO2, CXCR1 | HTR2C 1684/4885HTR2B 2213/4885CCNT1 388/4885 |
| US-20210317111-A1 | NOVEL MEDICAMENT FOR TREATING INFLAMMATORY BOWEL DISEASE | FABP2, SLC10A2, NFKBIA | HTR2C 2486/4885HTR2B 2987/4885CCNT1 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.